Hypermarcas (OTCMKTS:HYPMY) Shares Gap Down - Here's What Happened

Key Points

• Hypermarcas shares experienced a **gap down**, opening at **$3.82** after a previous close of **$3.97**, with a trading volume of **175 shares**.
• In a positive shift, **Scotiabank** upgraded Hypermarcas to a "**strong-buy**" rating, reflecting strong confidence in the stock's potential performance.
• Hypermarcas recently reported **$0.12 earnings per share** for the quarter, with a net margin of **11.28%** and a return on equity of **6.19%**.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $3.97, but opened at $3.82. Hypermarcas shares last traded at $3.82, with a volume of 175 shares trading hands.

Wall Street Analyst Weigh In

Separately, Scotiabank raised Hypermarcas to a "strong-buy" rating in a research report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, Hypermarcas presently has an average rating of "Strong Buy".

Hypermarcas Stock Performance

The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.63. The stock has a 50 day simple moving average of $4.24 and a two-hundred day simple moving average of $4.28. The stock has a market capitalization of $2.51 billion, a P/E ratio of 18.86 and a beta of 0.83.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.12 earnings per share for the quarter. Hypermarcas had a return on equity of 6.19% and a net margin of 11.28%.

Hypermarcas Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.